ExodusPoint Capital Management’s Black Diamond Therapeutics BDTX Stock Holding History

ExodusPoint Capital Management’s Portfolio BDTX Stock Details BDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-872,680	Closed	-$3.8M	–	1536
2024 Q3	$3.8M	Buy	872,680 +284,052	+48%	+$1.55M	0.02%	512
2024 Q2	$2.74M	Buy	588,628 +473,052	+409%	+$2.54M	0.02%	665
2024 Q1	$586K	Buy	115,576 +86,340	+295%	+$348K	﹤0.01%	1104
2023 Q4	$82K	Buy	+29,236	New	+$68.6K	﹤0.01%	1364
2021 Q4	–	Sell	-21,432	Closed	-$181K	–	2170
2021 Q3	$181K	Sell	21,432 -25,171	-54%	-$249K	﹤0.01%	1805
2021 Q2	$568K	Buy	+46,603	New	+$921K	0.01%	1302

Other funds holding BDTX

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ExodusPoint Capital Management's BDTX Position: Q4 2024 in Review

ExodusPoint Capital Management sold out of Black Diamond Therapeutics (BDTX) in Q4 2024, closing a stake of 872,680 shares — an estimated $3.8M sold.

ExodusPoint Capital Management first reported a position in BDTX in Q2 2021 and held it in 6 quarters. The position peaked at $3.8M in Q3 2024. 87 funds tracked by Wall St. Rank hold BDTX as of Q4 2024.

ExodusPoint Capital Management reported no remaining Black Diamond Therapeutics position as of Q4 2024 after selling out during the quarter.
ExodusPoint Capital Management sold 872,680 Black Diamond Therapeutics shares in Q4 2024, an estimated $3.8M.
ExodusPoint Capital Management first reported a position in Black Diamond Therapeutics in Q2 2021 and held it in 6 quarters.
ExodusPoint Capital Management's Black Diamond Therapeutics position peaked at $3.8M in Q3 2024.
87 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q4 2024.

Based on ExodusPoint Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.